Amaterasu LifeSciences: Revolutionizing Malaria Treatment with SIDMI
Amaterasu LifeSciences’ SIDMI is a groundbreaking single-dose injectable treatment for malaria, combining artemether and lumefantrine. It ensures 100% parasite clearance, improves patient compliance, and reduces side effects. With scalable production, SIDMI addresses drug resistance and is poised to transform malaria treatment globally, offering a cost-effective, patient-friendly solution to reduce mortality and morbidity.